Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most factual claims (class, mechanism in general terms, several adverse reactions, and brand/generic/patent-expiration assertions) are partially supported or not supported with the provided label excerpts. Indication-related claims are incomplete/misaligned with label wording for scope and qualifying details. Several safety/side-effect assertions are broader than what the label excerpts explicitly list.
Category Scores
Accurate Statements
Ertapenem is a carbapenem antibiotic.
Not explicitly supported in the provided excerpts (no explicit statement in the supplied label text about carbapenem class), so this is not counted as supported.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Not explicitly supported in the provided excerpts (mechanism of action not provided verbatim).
Ertapenem disruption of bacterial cell wall synthesis leads to bacterial cell lysis and death.
Not explicitly supported in the provided excerpts.
Common side effects of ertapenem include diarrhea, nausea, vomiting, headache, and rash.
Partially supported: the label excerpt lists diarrhea, nausea, headache; it does not list vomiting or rash as common drug-related adverse experiences in the provided excerpt.
Serious adverse reactions of ertapenem can include severe allergic reactions.
Supported in part: the label excerpt describes serious/anaphylactic hypersensitivity reactions and post-marketing anaphylaxis/anaphylactoid reactions.
Serious adverse reactions of ertapenem can include Clostridioides difficile-associated diarrhea.
Supported: label excerpt states CDAD has been reported with nearly all antibacterial agents, including ertapenem.
Serious adverse reactions of ertapenem can include seizures.
Supported: label excerpt reports seizures/CNS adverse experiences during treatment, and highlights risk considerations.
Serious adverse reactions of ertapenem can include liver problems.
Not supported in the provided excerpts.
Ertapenem is marketed under the brand name Invanz by Merck & Co.
Not supported in the provided excerpts.
Generic versions of ertapenem may be available from other manufacturers.
Not supported in the provided excerpts.
The composition of matter patent for ertapenem expired in the U.S. on October 1, 2022.
Not supported in the provided excerpts.
Patents covering specific synthesis methods for ertapenem may have different expiration dates.
Not supported in the provided excerpts.
Unsupported Statements
Ertapenem is a carbapenem antibiotic.
The provided label excerpts do not explicitly state the drug class as carbapenem.
Ertapenem is used to treat moderate to severe infections caused by susceptible bacteria.
Label excerpt provides specific indications but does not include phrasing about 'moderate to severe infections' caused by susceptible bacteria as a general indication statement.
Ertapenem is used to treat intra-abdominal infections caused by susceptible bacteria.
Label excerpt supports complicated intra-abdominal infections due to listed organisms, including adult and pediatric (3 months+) populations; the claim omits 'complicated' and does not reflect the label's specific organism-based indication wording.
Ertapenem is used to treat skin and skin structure infections caused by susceptible bacteria.
Label excerpt supports complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis, due to listed organisms; the claim omits key qualifiers ('complicated', diabetic foot without osteomyelitis) and organism specificity.
Ertapenem is used to treat community-acquired pneumonia caused by susceptible bacteria.
Label excerpt supports community acquired pneumonia due to specific organisms with susceptibility qualifiers; claim omits these specifics.
Ertapenem is used to treat gynecologic infections caused by susceptible bacteria.
Label excerpt supports acute pelvic infections (including postpartum endomyometritis, septic abortion, post-surgical gynecologic infections) due to listed organisms; claim is overbroad and omits the label's precise indication scope.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Mechanism of action details are not explicitly provided in the provided excerpts.
Ertapenem disruption of bacterial cell wall synthesis leads to bacterial cell lysis and death.
Mechanism of action details are not explicitly provided in the provided excerpts.
Common side effects of ertapenem include diarrhea, nausea, vomiting, headache, and rash.
The excerpt explicitly lists diarrhea, nausea, and headache as common drug-related adverse experiences; it does not list vomiting or rash in the provided common adverse experience list.
Serious adverse reactions of ertapenem can include liver problems.
The provided adverse reaction excerpts do not mention liver problems.
Ertapenem is marketed under the brand name Invanz by Merck & Co.
Brand/manufacturer information is not included in the provided label excerpts.
Generic versions of ertapenem may be available from other manufacturers.
Generic availability is not included in the provided label excerpts.
The composition of matter patent for ertapenem expired in the U.S. on October 1, 2022.
Patent expiration dates are not included in the provided label excerpts.
Patents covering specific synthesis methods for ertapenem may have different expiration dates.
Patent details are not included in the provided label excerpts.
Contradictions
Important Omissions
Indication qualifiers such as 'complicated' and organism-specific listings (and susceptibility qualifiers) are omitted from multiple indication claims (intra-abdominal, skin/skin structure, pneumonia, gynecologic/pelvic infections).
Importance:
Moderate
For common side effects, the claim includes 'vomiting' and 'rash' which are not shown in the provided 'most common' drug-related adverse experiences list; the claim also omits the label's specific common items (e.g., infused vein complication and vaginitis in females as listed).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overbroad/unqualified indication and adverse-reaction assertions (e.g., adding liver problems; omitting key indication qualifiers like 'complicated' and organism-specific listings; adding vomiting/rash without support) could mislead about what the labeled product is indicated for and what adverse reactions are common/serious.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts or omit important labeled qualifiers (indication scope/organism specificity; common adverse experience specifics; liver problem assertion; MOA/brand/patent assertions).
Suggested Improvement
Rephrase indication claims to match labeled indications exactly (include 'complicated' and organism lists/susceptibility qualifiers) and limit adverse reaction claims to those explicitly listed in the provided excerpts (e.g., diarrhea, nausea, headache; and hypersensitivity/CDAD/seizures). Remove or label as unverified statements that are not present in the supplied excerpts (carbapenem classification, detailed MOA, brand/manufacturer, patent expiration).